Changing the Landscape of Hypertension Management With SGLT2i

(Invited review)

  • Ines Bilić Ćurčić* Department of Pharmacology, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek; Clinic for Internal Medicine, University Hospital Center Osijek, Croatia
  • Vjera Ninčević Department of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health, Josip Juraj Strossmayer University of Osijek, Croatia
  • Silvija Canecki Varžić Clinic for Internal Medicine, University Hospital Center Osijek, Croatia; Department of Internal Medicine, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Croatia
  • Ivana Prpić Križevac Clinic for Internal Medicine, University Hospital Center Osijek, Croatia; Department of Internal Medicine, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Croatia
  • Jasminka Milas Ahić Clinic for Internal Medicine, University Hospital Center Osijek, Croatia; Department of Pathophysiology, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Croatia
  • Ivica Mihaljević Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Center Osijek, Croatia; Department of Nuclear Medicine and Oncology, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, Croatia

Abstract

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a newer class of drugs that have primarily been used in the treatment of type 2 diabetes. However, as new findings from clinical trials have become available, their indication has been expanded to include treatment of heart failure and chronic kidney disease without the presence of diabetes. The pathophysiological mechanisms of extraglycemic effects of SGLT2i are still being unraveled, but one of the most prominent consequences is a decrease in blood pressure, which has implications for hemodynamics and arterial stiffness. Recent findings indicate that this class of drugs has a beneficial effect on lowering nocturnal blood pressure (BP), with special importance in type 2 diabetes (DMT2), since unregulated nocturnal hypertension is associated with an increased incidence of cardiovascular (CV) events. In this mini-review, we have summarized current knowledge about the effects of SGLT2i on blood pressure, including office, home, and ambulatory BP, and potential implications for treatment of hypertension in diabetic and non-diabetic individuals, with positive effects on cardiorenal outcomes.


 

Published
Apr 27, 2022
How to Cite
BILIĆ ĆURČIĆ*, Ines et al. Changing the Landscape of Hypertension Management With SGLT2i. Southeastern European Medical Journal, [S.l.], v. 6, n. 1, p. 1-11, apr. 2022. ISSN 2459-9484. Available at: <http://seemedj.mefos.unios.hr/index.php/seemedj/article/view/247>. Date accessed: 03 july 2022. doi: http://dx.doi.org/10.26332/seemedj.v6i1.247.
Section
Articles